PCM
INO icon

Prelude Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Prelude Capital Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-208
Closed -$29K – 1611
2020
Q3 		$29K Sell
208
-9
-4% -$1.88K ﹤0.01% 1262
2020
Q2 		$70K Buy
217
+150
+224% +$24.1K ﹤0.01% 1056
2020
Q1 		$6K Buy
+67
New +$4.13K ﹤0.01% 1208

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Prelude Capital Management's INO Position: Q2 2020 in Review

Prelude Capital Management sold out of Inovio Pharmaceuticals (INO) in Q2 2020, closing a stake of 83 shares — an estimated $13.3K sold.

Prelude Capital Management first reported a position in INO in Q3 2014 and held it in 5 quarters. The position peaked at $18K in Q3 2017. 214 funds tracked by Wall St. Rank hold INO as of Q2 2020.

  • Prelude Capital Management reported no remaining Inovio Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Prelude Capital Management sold 83 Inovio Pharmaceuticals shares in Q2 2020, an estimated $13.3K.
  • Prelude Capital Management first reported a position in Inovio Pharmaceuticals in Q3 2014 and held it in 5 quarters.
  • Prelude Capital Management's Inovio Pharmaceuticals position peaked at $18K in Q3 2017.
  • 214 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2020.

Based on Prelude Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.